Athira Pharma (ATHA) Expected to Announce Earnings on Thursday

Athira Pharma (NASDAQ:ATHA) is anticipated to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 14, 2025 at 4:00 PM ET.

Athira Pharma (NASDAQ:ATHA) last released its earnings results on Thursday, August 7th. The company reported ($1.80) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.80). On average, analysts expect Athira Pharma to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Athira Pharma Price Performance

Shares of Athira Pharma stock opened at $4.18 on Tuesday. The firm has a market cap of $16.49 million, a price-to-earnings ratio of -0.27 and a beta of 3.01. Athira Pharma has a one year low of $2.20 and a one year high of $8.26. The stock’s 50-day moving average is $3.95 and its 200-day moving average is $3.56.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ATHA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, October 8th. Mizuho set a $4.00 target price on shares of Athira Pharma in a report on Friday, September 19th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Athira Pharma has an average rating of “Sell” and a consensus price target of $4.00.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.